Generic companies ink hepatitis C deal with BMS

26-01-2016

Generic companies ink hepatitis C deal with BMS

360b / Shutterstock.com

Pharmaceutical companies including Cipla and Natco Pharma have signed a sub-licensing deal enabling them to produce a generic version of Bristol Myers Squibb’s (BMS) hepatitis C drug Daclatasvir (daklinza).


Cipla, Natco, Emcure, Hetero, Bristol Myers Squibb, Hepatitis C, paye, daclatasvir, Greg Perry, Medicines Patent Pool, MPP, Rajeev Nannapaneni, Vik Thapar,

LSIPR